Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Chris Bizon is active.

Publication


Featured researches published by Chris Bizon.


The New England Journal of Medicine | 2012

Germline Mutations in HOXB13 and Prostate-Cancer Risk

Charles M. Ewing; Anna M. Ray; Ethan M. Lange; Kimberly A. Zuhlke; Christiane M. Robbins; Waibhav Tembe; Kathleen E. Wiley; Sarah D. Isaacs; Dorhyun Johng; Yunfei Wang; Chris Bizon; Guifang Yan; Marta Gielzak; Alan W. Partin; Vijayalakshmi Shanmugam; Tyler Izatt; Shripad Sinari; David Craig; S. Lilly Zheng; Patrick C. Walsh; James E. Montie; Jianfeng Xu; John D. Carpten; William B. Isaacs; Kathleen A. Cooney

BACKGROUND Family history is a significant risk factor for prostate cancer, although the molecular basis for this association is poorly understood. Linkage studies have implicated chromosome 17q21-22 as a possible location of a prostate-cancer susceptibility gene. METHODS We screened more than 200 genes in the 17q21-22 region by sequencing germline DNA from 94 unrelated patients with prostate cancer from families selected for linkage to the candidate region. We tested family members, additional case subjects, and control subjects to characterize the frequency of the identified mutations. RESULTS Probands from four families were discovered to have a rare but recurrent mutation (G84E) in HOXB13 (rs138213197), a homeobox transcription factor gene that is important in prostate development. All 18 men with prostate cancer and available DNA in these four families carried the mutation. The carrier rate of the G84E mutation was increased by a factor of approximately 20 in 5083 unrelated subjects of European descent who had prostate cancer, with the mutation found in 72 subjects (1.4%), as compared with 1 in 1401 control subjects (0.1%) (P=8.5x10(-7)). The mutation was significantly more common in men with early-onset, familial prostate cancer (3.1%) than in those with late-onset, nonfamilial prostate cancer (0.6%) (P=2.0x10(-6)). CONCLUSIONS The novel HOXB13 G84E variant is associated with a significantly increased risk of hereditary prostate cancer. Although the variant accounts for a small fraction of all prostate cancers, this finding has implications for prostate-cancer risk assessment and may provide new mechanistic insights into this common cancer. (Funded by the National Institutes of Health and others.).


Genetics in Medicine | 2013

An informatics approach to analyzing the incidentalome

Jonathan S. Berg; Michael Adams; Nassib Nassar; Chris Bizon; Kristy Lee; Charles Schmitt; Kirk C. Wilhelmsen; James P. Evans

Purpose:Next-generation sequencing has transformed genetic research and is poised to revolutionize clinical diagnosis. However, the vast amount of data and inevitable discovery of incidental findings require novel analytic approaches. We therefore implemented for the first time a strategy that utilizes an a priori structured framework and a conservative threshold for selecting clinically relevant incidental findings.Methods:We categorized 2,016 genes linked with Mendelian diseases into “bins” based on clinical utility and validity, and used a computational algorithm to analyze 80 whole-genome sequences in order to explore the use of such an approach in a simulated real-world setting.Results:The algorithm effectively reduced the number of variants requiring human review and identified incidental variants with likely clinical relevance. Incorporation of the Human Gene Mutation Database improved the yield for missense mutations but also revealed that a substantial proportion of purported disease-causing mutations were misleading.Conclusion:This approach is adaptable to any clinically relevant bin structure, scalable to the demands of a clinical laboratory workflow, and flexible with respect to advances in genomics. We anticipate that application of this strategy will facilitate pretest informed consent, laboratory analysis, and posttest return of results in a clinical context.Genet Med 2013:15(1):36–44


Genetics in Medicine | 2011

Next generation massively parallel sequencing of targeted exomes to identify genetic mutations in primary ciliary dyskinesia: implications for application to clinical testing

Jonathan S. Berg; James P. Evans; Margaret W. Leigh; Heymut Omran; Chris Bizon; Ketan K. Mane; Karen E. Weck; Maimoona A. Zariwala

Purpose: Advances in genetic sequencing technology have the potential to enhance testing for genes associated with genetically heterogeneous clinical syndromes, such as primary ciliary dyskinesia. The objective of this study was to investigate the performance characteristics of exon-capture technology coupled with massively parallel sequencing for clinical diagnostic evaluation.Methods: We performed a pilot study of four individuals with a variety of previously identified primary ciliary dyskinesia mutations. We designed a custom array (NimbleGen) to capture 2089 exons from 79 genes associated with primary ciliary dyskinesia or ciliary function and sequenced the enriched material using the GS FLX Titanium (Roche 454) platform. Bioinformatics analysis was performed in a blinded fashion in an attempt to detect the previously identified mutations and validate the process.Results: Three of three substitution mutations and one of three small insertion/deletion mutations were readily identified using this methodology. One small insertion mutation was clearly observed after adjusting the bioinformatics handling of previously described SNPs. This process failed to detect two known mutations: one single-nucleotide insertion and a whole-exon deletion. Additional retrospective bioinformatics analysis revealed strong sequence-based evidence for the insertion but failed to detect the whole-exon deletion. Numerous other variants were also detected, which may represent potential genetic modifiers of the primary ciliary dyskinesia phenotype.Conclusions: We conclude that massively parallel sequencing has considerable potential for both research and clinical diagnostics, but further development is required before widespread adoption in a clinical setting.


Bioinformatics | 2013

Imputation of coding variants in African Americans: better performance using data from the exome sequencing project

Qing Duan; Eric Yi Liu; Paul L. Auer; Guosheng Zhang; Ethan M. Lange; Goo Jun; Chris Bizon; Steven Buyske; Nora Franceschini; Christopher S. Carlson; Li Hsu; Alex P. Reiner; Ulrike Peters; Jeff Haessler; Keith R. Curtis; Christina L. Wassel; Jennifer G. Robinson; Lisa W. Martin; Christopher A. Haiman; Loic Le Marchand; Tara C. Matise; Lucia A. Hindorff; Dana C. Crawford; Themistocles L. Assimes; Hyun Min Kang; Gerardo Heiss; Rebecca D. Jackson; Charles Kooperberg; James G. Wilson; Gonçalo R. Abecasis

SUMMARY Although the 1000 Genomes haplotypes are the most commonly used reference panel for imputation, medical sequencing projects are generating large alternate sets of sequenced samples. Imputation in African Americans using 3384 haplotypes from the Exome Sequencing Project, compared with 2184 haplotypes from 1000 Genomes Project, increased effective sample size by 8.3-11.4% for coding variants with minor allele frequency <1%. No loss of imputation quality was observed using a panel built from phenotypic extremes. We recommend using haplotypes from Exome Sequencing Project alone or concatenation of the two panels over quality score-based post-imputation selection or IMPUTE2s two-panel combination. CONTACT [email protected]. SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.


Genetics in Medicine | 2017

Prenatal exome sequencing in anomalous fetuses: new opportunities and challenges

Neeta L. Vora; Bradford C. Powell; Alicia T. Brandt; Natasha T. Strande; Emily Hardisty; Kelly Gilmore; Ann Katherine M. Foreman; Kirk C. Wilhelmsen; Chris Bizon; Jason Reilly; Phil Owen; Cynthia M. Powell; Debra Skinner; Christine Rini; Anne Drapkin Lyerly; Kim Boggess; Karen E. Weck; Jonathan S. Berg; James P. Evans

PurposeWe investigated the diagnostic and clinical performance of exome sequencing in fetuses with sonographic abnormalities with normal karyotype and microarray and, in some cases, normal gene-specific sequencing.MethodsExome sequencing was performed on DNA from 15 anomalous fetuses and from the peripheral blood of their parents. Parents provided consent to be informed of diagnostic results in the fetus, medically actionable findings in the parents, and their identification as carrier couples for significant autosomal recessive conditions. We assessed the perceptions and understanding of exome sequencing using mixed methods in 15 mother−father dyads.ResultsIn seven (47%) of 15 fetuses, exome sequencing provided a diagnosis or possible diagnosis with identification of variants in the following genes: COL1A1, MUSK, KCTD1, RTTN, TMEM67, PIEZO1 and DYNC2H1. One additional case revealed a de novo nonsense mutation in a novel candidate gene (MAP4K4). The perceived likelihood that exome sequencing would explain the results (5.2 on a 10-point scale) was higher than the approximately 30% diagnostic yield discussed in pretest counseling.ConclusionExome sequencing had diagnostic utility in a highly select population of fetuses where a genetic diagnosis was highly suspected. Challenges related to genetics literacy and variant interpretation must be addressed by highly tailored pre- and posttest genetic counseling.


BMC Genomics | 2014

Variant calling in low-coverage whole genome sequencing of a Native American population sample

Chris Bizon; Michael Spiegel; Scott A. Chasse; Ian R. Gizer; Yun Li; Ewa P. Malc; Piotr A. Mieczkowski; Josh K Sailsbery; Xiaoshu Wang; Cindy L. Ehlers; Kirk C. Wilhelmsen

BackgroundThe reduction in the cost of sequencing a human genome has led to the use of genotype sampling strategies in order to impute and infer the presence of sequence variants that can then be tested for associations with traits of interest. Low-coverage Whole Genome Sequencing (WGS) is a sampling strategy that overcomes some of the deficiencies seen in fixed content SNP array studies. Linkage-disequilibrium (LD) aware variant callers, such as the program Thunder, may provide a calling rate and accuracy that makes a low-coverage sequencing strategy viable.ResultsWe examined the performance of an LD-aware variant calling strategy in a population of 708 low-coverage whole genome sequences from a community sample of Native Americans. We assessed variant calling through a comparison of the sequencing results to genotypes measured in 641 of the same subjects using a fixed content first generation exome array. The comparison was made using the variant calling routines GATK Unified Genotyper program and the LD-aware variant caller Thunder. Thunder was found to improve concordance in a coverage dependent fashion, while correctly calling nearly all of the common variants as well as a high percentage of the rare variants present in the sample.ConclusionsLow-coverage WGS is a strategy that appears to collect genetic information intermediate in scope between fixed content genotyping arrays and deep-coverage WGS. Our data suggests that low-coverage WGS is a viable strategy with a greater chance of discovering novel variants and associations than fixed content arrays for large sample association analyses.


Genome Medicine | 2017

ClinGen Pathogenicity Calculator: a configurable system for assessing pathogenicity of genetic variants

Ronak Y. Patel; Neethu Shah; Andrew R. Jackson; Rajarshi Ghosh; Piotr Pawliczek; Sameer Paithankar; Aaron Baker; Kevin Riehle; Hailin Chen; Sofia Milosavljevic; Chris Bizon; Shawn Rynearson; Tristan Nelson; Gail P. Jarvik; Heidi L. Rehm; Steven M. Harrison; Danielle R. Azzariti; Bradford C. Powell; Larry Babb; Sharon E. Plon; Aleksandar Milosavljevic

BackgroundThe success of the clinical use of sequencing based tests (from single gene to genomes) depends on the accuracy and consistency of variant interpretation. Aiming to improve the interpretation process through practice guidelines, the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) have published standards and guidelines for the interpretation of sequence variants. However, manual application of the guidelines is tedious and prone to human error. Web-based tools and software systems may not only address this problem but also document reasoning and supporting evidence, thus enabling transparency of evidence-based reasoning and resolution of discordant interpretations.ResultsIn this report, we describe the design, implementation, and initial testing of the Clinical Genome Resource (ClinGen) Pathogenicity Calculator, a configurable system and web service for the assessment of pathogenicity of Mendelian germline sequence variants. The system allows users to enter the applicable ACMG/AMP-style evidence tags for a specific allele with links to supporting data for each tag and generate guideline-based pathogenicity assessment for the allele. Through automation and comprehensive documentation of evidence codes, the system facilitates more accurate application of the ACMG/AMP guidelines, improves standardization in variant classification, and facilitates collaborative resolution of discordances. The rules of reasoning are configurable with gene-specific or disease-specific guideline variations (e.g. cardiomyopathy-specific frequency thresholds and functional assays). The software is modular, equipped with robust application program interfaces (APIs), and available under a free open source license and as a cloud-hosted web service, thus facilitating both stand-alone use and integration with existing variant curation and interpretation systems. The Pathogenicity Calculator is accessible at http://calculator.clinicalgenome.org.ConclusionsBy enabling evidence-based reasoning about the pathogenicity of genetic variants and by documenting supporting evidence, the Calculator contributes toward the creation of a knowledge commons and more accurate interpretation of sequence variants in research and clinical care.


American Journal of Ophthalmology | 2015

High Diagnostic Yield of Whole Exome Sequencing in Participants With Retinal Dystrophies in a Clinical Ophthalmology Setting

Kristy Lee; Jonathan S. Berg; Laura V. Milko; Kristy Crooks; Mei Lu; Chris Bizon; Phillips Owen; Kirk C. Wilhelmsen; Karen E. Weck; James P. Evans; Seema Garg

PURPOSE To assess the diagnostic yield and the practicality of implementing whole exome sequencing within a clinical ophthalmology setting. DESIGN Evaluation of a diagnostic protocol. METHODS setting: Patient participants were enrolled during clinical appointments in a university-based ophthalmic genetics clinic. PATIENT POPULATION Twenty-six patients with a variety of presumed hereditary retinal dystrophies. INTERVENTION Participants were offered whole exome sequencing in addition to clinically available sequencing gene panels between July 2012 and January 2013 to determine the molecular etiology of their retinal dystrophy. MAIN OUTCOME MEASURES Diagnostic yield and acceptability of whole exome sequencing in patients with retinal disorders. RESULTS Twenty-six of 29 eligible patients (∼90%) who were approached opted to undergo molecular testing. Each participant chose whole exome sequencing in addition to, or in lieu of, clinically available sequencing gene panels. Time to obtain informed consent was manageable in the clinical context. Whole exome sequencing successfully identified known pathogenic mutations or suspected deleterious variants in 57.7% of participants. Additionally, 1 participant had 2 autosomal dominant medically actionable incidental findings (unrelated to retinopathy) that were reported to enable the participant to take preventive action and reduce risk for future disease. CONCLUSIONS In this study, we identified the molecular etiology for more than half of all participants. Additionally, we found that participants were widely accepting of whole exome sequencing and the possibility of being informed about medically actionable incidental findings.


BMC Bioinformatics | 2012

ReQON: a Bioconductor package for recalibrating quality scores from next-generation sequencing data

Christopher R. Cabanski; Keary Cavin; Chris Bizon; Matthew D. Wilkerson; Joel S. Parker; Kirk C. Wilhelmsen; Charles M. Perou; J. S. Marron; D. Neil Hayes

BackgroundNext-generation sequencing technologies have become important tools for genome-wide studies. However, the quality scores that are assigned to each base have been shown to be inaccurate. If the quality scores are used in downstream analyses, these inaccuracies can have a significant impact on the results.ResultsHere we present ReQON, a tool that recalibrates the base quality scores from an input BAM file of aligned sequencing data using logistic regression. ReQON also generates diagnostic plots showing the effectiveness of the recalibration. We show that ReQON produces quality scores that are both more accurate, in the sense that they more closely correspond to the probability of a sequencing error, and do a better job of discriminating between sequencing errors and non-errors than the original quality scores. We also compare ReQON to other available recalibration tools and show that ReQON is less biased and performs favorably in terms of quality score accuracy.ConclusionReQON is an open source software package, written in R and available through Bioconductor, for recalibrating base quality scores for next-generation sequencing data. ReQON produces a new BAM file with more accurate quality scores, which can improve the results of downstream analysis, and produces several diagnostic plots showing the effectiveness of the recalibration.


American Journal of Medical Genetics | 2014

Association and ancestry analysis of sequence variants in ADH and ALDH using alcohol-related phenotypes in a Native American community sample.

Qian Peng; Ian R. Gizer; Ondrej Libiger; Chris Bizon; Kirk C. Wilhelmsen; Nicholas J. Schork; Cindy L. Ehlers

Higher rates of alcohol use and other drug‐dependence have been observed in some Native American (NA) populations relative to other ethnic groups in the US. Previous studies have shown that alcohol dehydrogenase (ADH) genes and aldehyde dehydrogenase (ALDH) genes may affect the risk of development of alcohol dependence, and that polymorphisms within these genes may differentially affect risk for the disorder depending on the ethnic group evaluated. We evaluated variations in the ADH and ALDH genes in a large study investigating risk factors for substance use in a NA population. We assessed ancestry admixture and tested for associations between alcohol‐related phenotypes in the genomic regions around the ADH1–7 and ALDH2 and ALDH1A1 genes. Seventy‐two ADH variants showed significant evidence of association with a severity level of alcohol drinking‐related dependence symptoms phenotype. These significant variants spanned across the entire 7 ADH gene cluster regions. Two significant associations, one in ADH and one in ALDH2, were observed with alcohol dependence diagnosis. Seventeen variants showed significant association with the largest number of alcohol drinks ingested during any 24‐hour period. Variants in or near ADH7 were significantly negatively associated with alcohol‐related phenotypes, suggesting a potential protective effect of this gene. In addition, our results suggested that a higher degree of NA ancestry is associated with higher frequencies of potential risk variants and lower frequencies of potential protective variants for alcohol dependence phenotypes.

Collaboration


Dive into the Chris Bizon's collaboration.

Top Co-Authors

Avatar

Kirk C. Wilhelmsen

Renaissance Computing Institute

View shared research outputs
Top Co-Authors

Avatar

Cindy L. Ehlers

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Charles Schmitt

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

James P. Evans

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Jonathan S. Berg

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Ketan K. Mane

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Phillips Owen

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bradford C. Powell

University of North Carolina at Chapel Hill

View shared research outputs
Researchain Logo
Decentralizing Knowledge